In-hospital initiation of dapagliflozin in patients hospitalized for acute heart failure (HF) did not significantly reduce the short-term risk of worsening HF or death, based on findings from the DAPA ...
Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock ...
Late-breaking clinical trials presented at ACC.26 focusing on coronary interventions included several looking at intravascular guidance in complex, high-risk procedures (IVUS-CHIP), bifurcation ...
A treatment-induced increase in plasma potassium levels reduced the risk of ventricular arrhythmias, in patients with ICDs and baseline plasma potassium levels of 4.3 mmol per liter or lower, based on ...
The size of a person’s midsection is a better indicator of cardiovascular disease risk when compared to their body mass index (BMI) alone, according to a study published in JACC, the flagship journal ...
Global collaboration is essential to reducing the burden of cardiovascular disease worldwide. To that end, ACC provides membership opportunities for clinicians practicing outside of the US.
In the ABYSS (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicated Myocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization) trial, interruption of ...
The Centers for Medicare and Medicaid Services (CMS) released the 2027 Inpatient Prospective Payment System (IPPS) final rule on July 31. The rule includes a net increase to inpatient hospital payment ...
The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...
HFpEF accounts for approximately half of all HF cases, yet therapeutic options remain limited. Steroidal mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone have ...
Patients with trivial, silent, isolated patent ductus arteriosus (PDA) should be discharged from cardiology care. Small PDAs may be followed infrequently in the clinic (every 2-3 years) to monitor for ...
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results